Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16849547rdf:typepubmed:Citationlld:pubmed
pubmed-article:16849547lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0105770lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0132555lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:16849547lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:16849547pubmed:issue14lld:pubmed
pubmed-article:16849547pubmed:dateCreated2006-7-19lld:pubmed
pubmed-article:16849547pubmed:abstractTextNitric oxide (NO.), an important mediator of inflammation, and beta-catenin, a component of the Wnt-adenomatous polyposis coli signaling pathway, contribute to the development of cancer. We have identified two T-cell factor 4 (Tcf-4)-binding elements (TBE1 and TBE2) in the promoter of human inducible NO synthase 2 (NOS2). We tested the hypothesis that beta-catenin regulates human NOS2 gene. Mutation in either of the two TBE sites decreased the basal and cytokine-induced NOS2 promoter activity in different cell lines. The promoter activity was significantly reduced when both TBE1 and TBE2 sites were mutated (P < 0.01). Nuclear extract from HCT116, HepG2, or DLD1 cells bound to NOS2 TBE1 or TBE2 oligonucleotides in electrophoretic mobility shift assays and the specific protein-DNA complexes were supershifted with anti-beta-catenin or anti-Tcf-4 antibody. Overexpression of beta-catenin and Tcf-4 significantly increased both basal and cytokine-induced NOS2 promoter activity (P < 0.01), and the induction was dependent on intact TBE sites. Overexpression of beta-catenin or Tcf-4 increased NOS2 mRNA and protein expression in HCT116 cells. Lithium chloride (LiCl), an inhibitor of glycogen synthase kinase-3beta, increased cytosolic and nuclear beta-catenin level, NOS2 expression, and NO. production in primary human and rat hepatocytes and cancer cell lines. Treatment with Wnt-3A-conditioned medium increased beta-catenin and NOS2 expression in fetal human hepatocytes. When administered in vivo, LiCl increased hepatic beta-catenin level in a dose-dependent manner with simultaneous increase in NOS2 expression. These data are consistent with the hypothesis that beta-catenin up-regulates NOS2 and suggest a novel mechanism by which the Wnt/beta-catenin signaling pathway may contribute to cancer by increasing NO. production.lld:pubmed
pubmed-article:16849547pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:languageenglld:pubmed
pubmed-article:16849547pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:citationSubsetIMlld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16849547pubmed:statusMEDLINElld:pubmed
pubmed-article:16849547pubmed:monthJullld:pubmed
pubmed-article:16849547pubmed:issn0008-5472lld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:GellerDavid...lld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:GuoZhongZlld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:DuQiangQlld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:ShaoLifangLlld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:HussainS...lld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:HePeijunPlld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:NagashimaMako...lld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:ParkKyung...lld:pubmed
pubmed-article:16849547pubmed:authorpubmed-author:SahaiRohitRlld:pubmed
pubmed-article:16849547pubmed:issnTypePrintlld:pubmed
pubmed-article:16849547pubmed:day15lld:pubmed
pubmed-article:16849547pubmed:volume66lld:pubmed
pubmed-article:16849547pubmed:ownerNLMlld:pubmed
pubmed-article:16849547pubmed:authorsCompleteYlld:pubmed
pubmed-article:16849547pubmed:pagination7024-31lld:pubmed
pubmed-article:16849547pubmed:dateRevised2011-11-2lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:meshHeadingpubmed-meshheading:16849547...lld:pubmed
pubmed-article:16849547pubmed:year2006lld:pubmed
pubmed-article:16849547pubmed:articleTitleRegulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling.lld:pubmed
pubmed-article:16849547pubmed:affiliationDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.lld:pubmed
pubmed-article:16849547pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16849547pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
pubmed-article:16849547pubmed:publicationTypeResearch Support, N.I.H., Intramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16849547lld:pubmed